Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
申请人:Miller Guy M.
公开号:US11021424B2
公开(公告)日:2021-06-01
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
本发明公开了治疗或抑制线粒体疾病的方法,如弗里德雷希共济失调(FRDA)、勒伯遗传性视神经病变(LHON)、线粒体肌病、脑病、乳酸中毒、中风(MELAS)或卡恩斯-赛尔综合征(KSS),以及用于本发明方法的化合物,如α-生育酚醌。本发明还公开了用于治疗其他疾病的方法和化合物。本发明还公开了用于评估受试者代谢状态和治疗效果的能量生物标志物。还公开了调节、正常化或增强能量生物标志物的方法,以及用于此类方法的化合物。